Moderna rises as overseas COVID vaccine sales drive Q3 beat, guidance hike

What happened

Moderna reported $1.3 billion in third-quarter 2026 revenue, up about 29% year over year, as international COVID vaccine sales beat expectations. It recorded $162 million in net income versus a $200 million loss a year earlier, raised its full-year growth outlook, and lowered its 2026 capital spending estimate to about $200 million.

Confirmed

Global impact / market context

Stronger overseas vaccine sales lifted revenue, while lower research and development costs helped turn a year-earlier loss into a profit. The higher growth outlook signals management expects momentum to continue; reduced planned capital spending could also preserve cash, although the article does not quantify future cash effects.

Analyst inference

The results followed a 7% share-price drop in the prior session, and Moderna shares rebounded in premarket trading after the report. Revenue growth exceeded the consensus forecast, while the revised growth outlook was above the cited estimate, giving investors better current results and expectations to weigh.

Confirmed

What to watch

1. Track whether international COVID vaccine sales continue supporting revenue in coming quarters; the reported growth relied mainly on improved sales in those markets. Analyst inference
2. Watch upcoming results or guidance updates for evidence that Moderna can deliver its raised full-year growth outlook, which would support revenue expectations for the business. Analyst inference
3. Follow whether 2026 capital spending stays near the revised estimate of about $200 million, below the earlier range, potentially leaving more cash available for other needs. Analyst inference

Evidence

• seekingalpha.com